298 related articles for article (PubMed ID: 17367502)
1. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling.
Jarrar MH; Baranova A
J Cell Mol Med; 2007; 11(1):71-87. PubMed ID: 17367502
[TBL] [Abstract][Full Text] [Related]
2. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
4. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling.
Mughal A; Kumar D; Vikram A
Eur J Pharmacol; 2015 Dec; 768():217-25. PubMed ID: 26542126
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.
Ferruzzi P; Ceni E; Tarocchi M; Grappone C; Milani S; Galli A; Fiorelli G; Serio M; Mannelli M
J Clin Endocrinol Metab; 2005 Mar; 90(3):1332-9. PubMed ID: 15585569
[TBL] [Abstract][Full Text] [Related]
6. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
7. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy and chemoprevention by thiazolidinediones.
Fröhlich E; Wahl R
Biomed Res Int; 2015; 2015():845340. PubMed ID: 25866814
[TBL] [Abstract][Full Text] [Related]
9. Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer.
Bahrambeigi S; Badalzadeh R; Shafiei-Irannejad V; Alizadeh A
Crit Rev Oncog; 2019; 24(3):251-258. PubMed ID: 32422023
[TBL] [Abstract][Full Text] [Related]
10. PPARγ agonists upregulate sphingosine 1-phosphate (S1P) receptor 1 expression, which in turn reduces S1P-induced [Ca(2+)]i increases in renal mesangial cells.
Koch A; Völzke A; Puff B; Blankenbach K; Meyer Zu Heringdorf D; Huwiler A; Pfeilschifter J
Biochim Biophys Acta; 2013 Nov; 1831(11):1634-43. PubMed ID: 23906789
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
12. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
13. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones.
Weng JR; Chen CY; Pinzone JJ; Ringel MD; Chen CS
Endocr Relat Cancer; 2006 Jun; 13(2):401-13. PubMed ID: 16728570
[TBL] [Abstract][Full Text] [Related]
14. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation.
Betz MJ; Shapiro I; Fassnacht M; Hahner S; Reincke M; Beuschlein F;
J Clin Endocrinol Metab; 2005 Jul; 90(7):3886-96. PubMed ID: 15886257
[TBL] [Abstract][Full Text] [Related]
16. Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation.
Hondares E; Mora O; Yubero P; Rodriguez de la Concepción M; Iglesias R; Giralt M; Villarroya F
Endocrinology; 2006 Jun; 147(6):2829-38. PubMed ID: 16513826
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents.
Tureyen K; Kapadia R; Bowen KK; Satriotomo I; Liang J; Feinstein DL; Vemuganti R
J Neurochem; 2007 Apr; 101(1):41-56. PubMed ID: 17394460
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
19. The potential of antidiabetic thiazolidinediones for anticancer therapy.
Galli A; Mello T; Ceni E; Surrenti E; Surrenti C
Expert Opin Investig Drugs; 2006 Sep; 15(9):1039-49. PubMed ID: 16916271
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.
Hazra S; Batra RK; Tai HH; Sharma S; Cui X; Dubinett SM
Mol Pharmacol; 2007 Jun; 71(6):1715-20. PubMed ID: 17412838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]